熱門資訊> 正文
Vaxcyte启动5亿美元公开发行股票和认购证
2026-01-30 05:20
- Vaxcyte (PCVX) on Thursday said that it has commenced an underwritten public offering of $500 million of common stock and pre-funded warrants.
- The clinical-stage vaccine developer said all securities in the offering will be sold by the company and that it intends to grant underwriters a 30-day option to purchase up to an additional $75 million of common stock, including shares underlying the pre-funded warrants.
- The offering is subject to market and other conditions, and there is no assurance on the timing, size or terms of completion, the company said.
- PCVX -3.91% after hours to $50.75.
- Source: Press Release
More on Vaxcyte
- Vaxcyte: Financial Durability And The Case For Disruption
- Vaxcyte, Inc. (PCVX) Presents at Jefferies London Healthcare Conference 2025 - Slideshow
- Vaxcyte, Inc. (PCVX) Presents at Jefferies London Healthcare Conference 2025 Transcript
- Moderna, vaccine makers decline following FDA official comments on future approvals
- Seeking Alpha’s Quant Rating on Vaxcyte
推薦文章
美股機會日報 | 凌晨3點！美聯儲將公佈1月貨幣政策會議紀要，納指期貨漲近0.5%；13F大曝光！巴菲特連續三季減持蘋果
美股機會日報 | 阿里發佈千問3.5！性能媲美Gemini 3；馬斯克稱Cybercab將於4月開始生產
港股周報 | 中國大模型「春節檔」打響！智譜周漲超138%；鉅虧超230億！美團周內重挫超10%
一周財經日曆 | 港美股迎「春節+總統日」雙假期！萬億零售巨頭沃爾瑪將發財報
從軟件到房地產，美國多板塊陷入AI恐慌拋售潮
Meta計劃為智能眼鏡添加人臉識別技術
危機四伏，市場卻似乎毫不在意
財報前瞻 | 英偉達Q4財報放榜在即！高盛、瑞銀預計將大超預期，兩大關鍵催化將帶來意外驚喜？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
